| 包装: | 1mg |
| 规格: | 98% |
| 市场价: | 4370元 |
| 分子量: | 738 |
Background:
Erythromycin-13C-d3is intended for use as an internal standard for the quantification of erythromycin by GC- or LC-MS. Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.1It is active against a host of bacterial genera, includingStreptococcus, Staphylococcus, andHaemophilus(MIC90s = 0.015-2.0 mg/l).2Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth ofS. aureusin a mouse model of thigh infection.3It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4in vitrowith IC50values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.4,5Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.
1.Wilson, D.N.The A-Z of bacterial translation inhibitorsCrit. Rev. Biochem. Mol. Biol.44(6)393-433(2009) 2.Kanatani, M.S., and Guglielmo, B.J.The new macrolides. Azithromycin and clarithromycinWestern J. Med.160(1)31-37(1994) 3.Hoogeterp, J.J., Mattie, H., and van Furth, R.Activity of erythromycin and clindamycin in an experimental Staphylococcus aureus infection in normal and granulocytopenic mice. A comparative in vivo and in vitro studyScand. J. Infect. Dis.25(1)123-132(1993) 4.Westphal, J.F.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycinBr. J. Clin. Pharmacol.50(4)285-295(2000) 5.Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., et al.Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequencesClin. Pharmacol. Ther.64(3)278-285(1998)
m.cnreagent.com